ライフサイエンスコーパス: microglobulin

1 d species origin of the MHC-I L chain (beta2-microglobulin).

2 domain and covalently linked to human beta2-microglobulin).

3 lls, plasma cell labeling index, and beta(2) microglobulin).

4 dney function (creatinine, cystatin C, beta2-microglobulin).

5 and higher lactate dehydrogenase and beta-2-microglobulin.

6 he amyloidogenicity of the full-length beta2-microglobulin.

7 ed upon Zn(II) binding to the protein beta-2-microglobulin.

8 amyloid consists of Asp76Asn variant beta(2)-microglobulin.

9 fully with the amyloidogenic protein beta(2)-microglobulin.

10 ne kidney II cells together with human beta2-microglobulin.

11 g MHC class I, mannose receptor, and beta(2)-microglobulin.

12 igher ultrafiltration rate, and higher beta2-microglobulin.

13 of Cu(II) binding on the structure of beta-2-microglobulin.

14 ligands, nor does it associate with beta(2)-microglobulin.

15 helators haptoglobin, hemopexin, and alpha1- microglobulin.

16 y the tissue distribution of wild type beta2-microglobulin.

17 o the fibrillogenesis of the wild-type beta2-microglobulin.

18 asmacytic infiltration 70% or greater, beta2-microglobulin 4.0 mg/dL or greater, and albumin 3.5 g/dL

19 calcium, 9.1 mg/dL; albumin, 3.4 g/dL; beta2-microglobulin, 5.7 mg/L; lactate dehydrogenase (LDH), 39

20 uced double knockout mice for Bmp6 and beta2-microglobulin (a surrogate for the loss of Hfe) and for

21 loid fibrils formed from full-length beta(2)-microglobulin, a 99-residue protein involved in clinical

22 vidual counts were compared to that of beta2 microglobulin, a housekeeping gene.

23 hen determined the Zn binding site of beta-2-microglobulin, a protein associated with metal-induced a

24 ates, and (2) a compensatory rise in alpha-1 microglobulin (A1M) relative to hemopexin concentration

25 ated with a compensatory increase in alpha-1-microglobulin (A1M), resulting in an up to 10-fold highe

26 ing independent characteristics: age, beta-2 microglobulin, absolute lymphocyte count, sex, Rai stage

27 Previous studies of beta(2)-microglobulin aggregation have not shown such amyloidoge

28 ry excretion of blood plasma proteins alpha1-microglobulin, albumin, and IgG.

29 We did not detect changes in urinary alpha1-microglobulin, albumin, or IgG excretion.

30 due long) disulfide-containing protein beta2-microglobulin allowed the backbone amide protection to b

31 ion of 0.025%, whereas albumin and alpha(1) -microglobulin (alpha(1) -m) are reabsorbed by 'high' eff

32 This model predicts albumin, alpha(1) -microglobulin (alpha(1) -m), beta(2) -microglobulin (bet

33 alues were superior to those for NAG, alpha1-microglobulin, alpha1-acid glycoprotein, fractional excr

34 promising therapeutic implications in beta2-microglobulin amyloid-related diseases.

35 was identified as the plasma protein alpha1-microglobulin, an established megalin/cubilin ligand.

36 (99m)Tc-DMSA is filtered bound to alpha1-microglobulin and accumulates in the kidneys by megalin/

37 minidase (NAG) by enzyme measurement, alpha1-microglobulin and alpha(1)-acid glycoprotein by immunone

38 heory (ANT) to amyloid nucleation of beta(2)-microglobulin and amyloid beta(40) allows us to predict

39 Fibril formation of beta2-microglobulin and associated inflammation occur in patie

40 Levels of beta-2 microglobulin and CD40 antigen and presence of hepatitis

41 analysis, several proteins, including beta-2 microglobulin and CD40, correlated with GFR changes over

42 ore functional loss at P22, including beta-2 microglobulin and Cx3cr1, and during vision loss at P31

43 developed NOD mice expressing human beta(2)-microglobulin and HLA-A*1101 or HLA-B*0702, which are re

44 ructure of an amyloidogenic state of beta(2)-microglobulin and how it may corrupt a soluble counterpa

45 eropolymeric fibrils formed from human beta2-microglobulin and its truncated variant DeltaN6.

46 mational properties of acid-unfolded beta(2)-microglobulin and its variants at pH 2.5 as measured by

47 penia, hypercalcemia, elevated serum beta(2)-microglobulin and lactate dehydrogenase levels, as well

48 tages II and III, incorporating high beta(2)-microglobulin and low albumin, are considered to predict

49 d pathological properties of wild type beta2-microglobulin and of the D76N variant offers a unique op

50 i>0) had higher levels of IgG, IgM, alpha-1-microglobulin and RBP.

51 prognostic marker and can be used with beta2 microglobulin and t(4;14) to identify a group of patient

52 Addition of alpha1-microglobulin and TFF-3 resulted in a nonsignificant net

53 ed on univariable regression analyses, beta2-microglobulin and the number of O-FC courses were signif

54 he antigen-processing pathway, such as beta2-microglobulin and transporters associated with antigen p

55 nine, but did not correlate with age, beta-2-microglobulin, and CA.

56 s lacking MHC class I, MHC class II, beta(2)-microglobulin, and CD1, as well as tumor cell lines from

57 ar composition of antigenic peptide, beta(2)-microglobulin, and H chain connected by flexible linkers

58 ly assembled proteins, namely peptide, beta2 microglobulin, and heavy chain.

59 fluid lactate dehydrogenase isozyme 5, beta2-microglobulin, and immunoglobulin heavy chain rearrangem

60 injury markers (clusterin, cystatin-C, beta2-microglobulin, and liver fatty acid binding protein-1) t

61 s has been described for amyloid beta, beta2-microglobulin, and prion proteins.

62 del(11q), IGHV mutation status, serum beta2-microglobulin, and serum thymidine kinase.

63 previously showed that mice lacking beta(2)-microglobulin are highly susceptible to tumors induced b

64 in association with MHC-I H chains and beta2-microglobulin as a trimolecular complex.

65 Using myoglobin, cytochrome c, and beta-2-microglobulin as model protein systems, we demonstrate f

66 row activity-strongly correlated with beta-2-microglobulin as surrogate imaging markers of tumor burd

67 um IL-6, monoclonal immunoglobulin and beta2-microglobulin, as well as bone marrow plasma cell percen

68 associated with Alzheimer's disease, beta(2)-microglobulin associated with dialysis-related amyloidos

69 cell surface of APC as both classical beta2-microglobulin-associated B27 and B27 free H chain forms

70 LILRB1 exclusively bound folded beta(2)-microglobulin-associated class I, whereas LILRB2 bound b

71 ogeneous density of peptide-associated beta2-microglobulin-associated HLA HC (pepA-beta2aHC), peptide

72 uced complex formation between m06 and beta2-microglobulin-associated MHC-I.

73 ein presented by Q9, a member of the beta(2) microglobulin-associated Qa-2 family.

74 abnormalities, age at least 60 years, beta2-microglobulin at least 2 mg/L, albumin less than 3.5 g/d

75 ion of the 100-residue protein human beta(2)-microglobulin at pH 2.5, commencing from an acid-denatur

76 vious regimens, and concentration of beta(2) microglobulin at screening.

77 ts transgenic for human HLA-B27 and beta(2) -microglobulin (B27-transgenic rats), colitis and periphe

78 t lack murine MHC class I and II [NSG-beta-2-microglobulin ( B2M) (null) ( IA IE)(null) and NSG -( K(

79 t or levels of the housekeeping genes beta-2 microglobulin (B2M) and glyceraldehyde-3-phosphate dehyd

80 Disruption of the Beta-2 Microglobulin (B2M) gene eliminates surface expression o

81 beta-2-microglobulin (B2M) is the most commonly altered gene in

82 er, previous nonprotocol therapy, and beta-2 microglobulin (B2M) of 3 mg/dL or greater as prognostic

83 coding the antigen-presenting protein beta-2-microglobulin (B2M) was identified in a third patient.

84 Here we identify beta2-microglobulin (B2M), a component of major histocompatibi

85 nanoparticle (MN) probe that targets beta(2) microglobulin (B2M), a key component of the major histoc

86 ns or loss of heterozygosity (LOH) in beta-2-microglobulin (B2M), an essential component of MHC class

87 on with cytolytic activity, including beta-2-microglobulin (B2M), HLA-A, -B and -C and Caspase 8 (CAS

88 tudies confirmed that this protein was beta2-microglobulin (B2M).

89 o patterns: the most common contained beta-2 microglobulin (B2M, m/z=11,732) plus one or more peaks a

90 igated the impaired serum clearance in beta2-microglobulin (B2M-/-) deficient mice.

91 Age, beta2-microglobulin, best hematologic response, number of cort

92 ha(1) -microglobulin (alpha(1) -m), beta(2) -microglobulin (beta(2) -m) and retinol-binding protein 4

93 beta(2) -Microglobulin (beta(2) -m) and retinol-binding protein 4

94 Beta(2)-microglobulin (beta(2)m) amyloid deposits are linked to

95 MHC class I molecules and beta(2)-microglobulin (beta(2)m) are membrane glycoproteins that

96 n study is presented using the protein beta2-microglobulin (beta(2)M) as the model system.

97 lity control of CD1 heavy chain (HC).beta(2)-microglobulin (beta(2)m) complexes is unclear.

98 ltaN6, a truncation variant of human beta(2)-microglobulin (beta(2)m) found in amyloid deposits in th

99 lation of the immunoglobulin protein beta(2)-microglobulin (beta(2)m) into amyloid plaques in the joi

100 The D76N variant of human beta(2)-microglobulin (beta(2)m) is the causative agent of a her

101 Beta(2)-microglobulin (beta(2)m) is the major structural compone

102 Upon self-recognition of beta(2)-microglobulin (beta(2)M) molecules, PIR-B served as a pe

103 They include defects in beta(2)-microglobulin (beta(2)m) synthesis, loss of the gene(s)

104 rotein (heavy chain) associated with beta(2)-microglobulin (beta(2)m) that presents lipid antigens to

105 en-induced AHR, however, develops in beta(2)-microglobulin (beta(2)m)(-/-) mice, which lack classical

106 id-like fibrils formed in vitro from beta(2)-microglobulin (beta(2)m), the amyloid fibril protein ass

107 the naturally amyloidogenic protein beta(2)-microglobulin (beta(2)m), to determine the solution stru

108 riant (DeltaN6) of the human protein beta(2)-microglobulin (beta(2)m), which assembles into amyloid f

109 I recognition by alphabeta T cells, beta(2)-microglobulin (beta(2)m)-associated MHC class I molecule

110 id-like fibrils formed in vitro from beta(2)-microglobulin (beta(2)m).

111 f nucleation and elongation of human beta(2)-microglobulin (beta(2)m).

112 NDINGS: Longitudinal evaluation of betaeta-2 microglobulin (beta-2 m), neopterin and suPAR soluble ur

113 associated with CR included age and beta(2)-microglobulin (beta-2M).

114 reater susceptibility than CD8(-/-), beta(2)-microglobulin(-/-) (beta(2)m(-/-)), or WT mice to infect

115 i stage (P < .001), higher levels of beta(2)-microglobulin (beta2-M) (P < .001), and the absence of m

116 Beta2-microglobulin (beta2-m) can form dialysis-related amyloi

117 dy demonstrates for the first time how beta2-microglobulin (beta2-M) supports lethal metastasis in vi

118 a (Abeta) (1-40) and on that from D76N beta2-microglobulin (beta2-m) which is related to hereditary s

119 4; P values=0.007 to <0.001), whereas alpha1-microglobulin, beta2-microglobulin, KIM-1, and TFF-3 ass

120 reated patients < 70 years with serum beta-2 microglobulin (beta2M) >/= 4 mg/L.

121 The human protein beta2-microglobulin (beta2m) aggregates as amyloid fibrils in

122 re we show that the internalization of beta2-microglobulin (beta2m) amyloid fibrils is dependent on f

123 ed that ESAT-6 protein interacts with beta-2-microglobulin (beta2M) and affects class I Ag presentati

124 ells, CD1d associates prematurely with beta2-microglobulin (beta2m) and is able to rapidly exit the e

125 a3 domains of the H2D(d) H chain and beta(2)-microglobulin (beta2m) and is the functional binding sit

126 ssical heterotrimeric complexes with beta(2)-microglobulin (beta2m) and peptide and (beta2m free) fre

127 of the amyloid fibril-forming protein beta2-microglobulin (beta2m) and the molecular chaperone alpha

128 Using beta-2-microglobulin (beta2m) as a model amyloid-forming protei

129 Here, using beta2-microglobulin (beta2m) as a model system, we show that t

130 Here, using the protein beta-2-microglobulin (beta2m) as a model, we measure the kineti

131 ed amyloidosis is the accumulation of beta-2-microglobulin (beta2m) as amyloid fibrils in the musculo

132 on of the common MHC class I component beta2-microglobulin (beta2M) by cancer cells directly protecte

133 In dialysis patients, beta-2 microglobulin (beta2m) can aggregate and eventually form

134 Previously, one report described beta2-microglobulin (beta2m) deficiency as another monogenetic

135 Beta-2-microglobulin (beta2m) deposits as amyloid fibrils in th

136 dulators upon membrane interactions of beta2-microglobulin (beta2m) fibrils.

137 In dialysis patients, the protein beta2-microglobulin (beta2m) forms amyloid fibrils in a condit

138 t monoclonal antibodies (mAbs) against beta2-microglobulin (beta2M) have a remarkably strong apoptoti

139 genic and nonamyloidogenic variants of beta2-microglobulin (beta2m) in atomic detail.

140 Beta-2 microglobulin (beta2m) is a small globular protein impli

141 Beta-2 Microglobulin (beta2m) is a small, globular protein, wit

142 beta-2 microglobulin (beta2m) is an amyloidogenic protein invol

143 beta2-Microglobulin (beta2M) is believed to have arisen in a b

144 ession of FcRn or its binding partner beta 2 microglobulin (beta2M) renders cells resistant to infect

145 Beta-2-microglobulin (beta2m) self-associates into fibrillar am

146 ogenase (Gapdh), beta-actin (Actb), or beta2-microglobulin (beta2m) showed the highest fluctuation wi

147 Human D76N beta2-microglobulin (beta2m) variant is the prototype of unsta

148 beta2-Microglobulin (beta2m), a key component of the major his

149 sional flow on the aggregation of BSA, beta2-microglobulin (beta2m), granulocyte colony stimulating f

150 The protein factor beta2-microglobulin (beta2M), purified from the conditioned me

151 ing structural variant, D76N, of human beta2-microglobulin (beta2m), the ubiquitous light chain of cl

152 the amyloidogenesis mechanism of human beta2-microglobulin (beta2m), which is thought to be triggered

153 compare the native state dynamics of Beta-2 microglobulin (beta2m), whose aggregation is associated

154 We used B6 Ly49C-transgenic and B6 beta2 microglobulin (beta2m)-knockout Ly49C-transgenic mice to

155 in the naturally amyloidogenic protein beta2-microglobulin (beta2m).

156 ived from the amyloidogenic E chain of beta2-microglobulin (beta2m).

157 of ThT with two alternative states of beta-2 microglobulin (beta2m); one monomeric, the other an amyl

158 IL-2R-alpha (sIL-2R-alpha) and soluble beta2-microglobulin (beta2mu) (P < .001), and prolonged surviv

159 highly enriched proteins, including alpha-1 microglobulin/bikunin precursor, pigment epithelium-deri

160 ein C-II, serum amyloid A (SAA), and alpha-1-microglobulin/bikunin precursor.

161 The beta2-microglobulin -binding nanobody, Nb24, more potently inh

162 Pattern 2 lacked beta-2 microglobulin but contained several degradation products

163 ith oligomeric prefibrillar species of beta2-microglobulin but not with monomeric or fibrillar beta2-

164 s positively linked to high levels of beta-2-microglobulin, C-reactive protein, and lactate dehydroge

165 he amyloid transformation of wild-type beta2-microglobulin can be induced by the variant only after i

166 ng the binding ligand derived from the beta2-microglobulin chain of the human MHC class I molecule (J

167 e FcRn H chain alone or FcRn H chain-beta(2)-microglobulin complex and appeared to be maintained thro

168 d by three factors: normal or elevated beta2 microglobulin concentration at registration (</=2.5 mg/L

169 risk on the basis of cytogenetics and beta2-microglobulin concentrations.

170 r, monocyte chemotactic protein-1, and beta2-microglobulin correlated well with survival and may serv

171 Four markers (albumin, beta-2-microglobulin, cystatin C, and osteopontin) were undetec

172 The natural human variant of beta(2)-microglobulin (D76N beta(2)-m) is associated with a fata

173 The amyloidogenic variant of beta2-microglobulin, D76N, can readily convert into genuine fi

174 tudies on the amyloidogenic variant of beta2-microglobulin, D76N, causing hereditary systemic amyloid

175 9(+) subsets in BMC rejection by using beta2-microglobulin deficient (beta2m(-/-)) mice as donors.

176 o a combined class I-deficient mouse (beta-2 microglobulin deficient; beta2m(0)) and class II-deficie

177 i Nine Mile phase I vaccine (PIV) in beta(2)-microglobulin-deficient (B2m KO) and MHC-II-deficient (M

178 NK cells from beta(2)-microglobulin-deficient (B2m(-/-)) and wild-type mice ex

179 rus 68 (gammaHV68) infection of BALB beta(2)-microglobulin-deficient (BALB beta(2)m(-/-)) mice provid

180 generated K14-OVA Tg chimeras using beta(2)-microglobulin-deficient (beta(2)m) congenic donor bone m

181 es in nonobese diabetic/LtSz-scid/scid beta2 microglobulin-deficient mice engrafted with human CD34(+

182 urden compared with that of infected beta(2)-microglobulin-deficient mice that lack MHC class Ib-rest

183 They also contributed to beta2 microglobulin-deficient target cell destruction in vivo.

184 loidosis (DRA) is a cleaved variant of beta2-microglobulin (DeltaN6) lacking the first six N-terminal

185 clearly indicate the importance of a beta(2)-microglobulin-dependent but CD8 T-cell- and iNK T-cell-i

186 cells express alphabeta TCRs, neither beta2-microglobulin-dependent MHC class I nor any MHC class II

187 strated induction of a population of beta(2)-microglobulin-dependent, MHC class Ib-restricted CD8(+)

188 es not contact the MHCI alpha(2)- or beta(2)-microglobulin domains.

189 of PCLI response was independent of beta(2)-microglobulin, elevated creatinine, serum M-spike respon

190 d-promoted de novo fibril formation of beta2-microglobulin even at substoichiometric concentration.

191 potential extracellular chaperone for beta2-microglobulin even in moderately acidic conditions relev

192 tly reduce urinary angiotensinogen and beta2-microglobulin excretion.

193 pared to wild-type or to HLA-B7/human beta2 -microglobulin-expressing monocytes.

194 t here on the critical importance of beta(2)-microglobulin expression during murine K. pneumoniae bac

195 ody, Nb24, more potently inhibits D76N beta2-microglobulin fibrillogenesis than doxycycline with comp

196 usly described inhibitors of wild type beta2-microglobulin fibrillogenesis, doxycycline and single do

197 ity similar to that of homogenous D76N beta2-microglobulin fibrils and significantly higher than the

198 sults suggest that the surface of D76N beta2-microglobulin fibrils can favor the transition of the wi

199 -type even once it is absorbed on D76N beta2-microglobulin fibrils.

200 binding more strongly to HLA-B27 (B27) beta2-microglobulin free H chain (FHC) dimers than other HLA-c

201 f patients had a 17p deletion; 64% had beta2-microglobulin > 3.5 mg/L.

202 Multivariate analysis identified beta(2)-microglobulin >/= 3 mg/L (P < .001) and age >/= 40 years

203 ncology Group performance status >/=1, beta2-microglobulin >/=3.5 mg/L, TK >/=10 U/L, unmutated IGHV,

204 e >/=65 years, male gender, levels of beta-2-microglobulin >5.5 mg/L, and multiple myeloma relapse.

205 ws: TP53 aberration, prior treatment, beta-2 microglobulin >= 5 mg/L, and lactate dehydrogenase > 250

206 four factors (one point each; serum beta(2)-microglobulin >=5 mg/dL, lactate dehydrogenase >upper li

207 ts transgenic for HLA-B27 and human beta(2) -microglobulin (hbeta(2) m) spontaneously develop epididy

208 major constituents, full-length human beta2-microglobulin (hbeta2m) and a truncation variant, DeltaN

209 The amyloidogenic protein human beta2-microglobulin (hbeta2m) can co-polymerize with its N-ter

210 arthritis that develops in B27/human beta(2)-microglobulin (Hubeta(2)m)-transgenic rats.

211 umin, retinol binding protein (RBP), alpha-1-microglobulin, IgG and IgM were measured in banked urine

212 Using beta2-microglobulin, immunoglobulin G1, and human growth hormo

213 f a prototypical amyloidogenic system, beta2-microglobulin in solution and in microcrystalline state.

214 and binds to MHC class I coupled with beta2-microglobulin in the endoplasmic reticulum.

215 By application to amyloid assembly of beta2-microglobulin in vitro under constant mechanical stirrin

216 II NKT cells, after interaction with a beta2-microglobulin-independent CD1d receptor.

217 al HLA-C ligands, can bind to the same beta2-microglobulin-independent ligand as KIR2DS2.

218 R2DS2 reporter responses, indicating a beta2-microglobulin-independent ligand for KIR2DS2.

219 Furthermore, tumor recognition was beta(2)-microglobulin-independent.

220 frequently reported concentrations of beta2-microglobulin, indoxyl sulfate, homocysteine, uric acid,

221 tform that partially overlaps with the beta2-microglobulin interface on the MHC-I heavy chain, consis

222 beta2-microglobulin is essential for the association between T

223 Fibrillar beta2-microglobulin is resistant to lysosomal degradation.

224 beta2-Microglobulin is responsible for systemic amyloidosis af

225 <0.001), whereas alpha1-microglobulin, beta2-microglobulin, KIM-1, and TFF-3 associated with death wi

226 comes in proportional hazards models; alpha1-microglobulin, Kim-1, and TFF-3 predicted all-cause mort

227 In beta2-microglobulin knock out mice, the D76N beta2-microglobul

228 ing cells were also undiminished after beta2-microglobulin knockdown, and they were not blocked by an

229 psychological stress and OVA-loaded beta(2)-microglobulin knockout "donor" cells that cannot present

230 y in protective immunity, we immunized beta2-microglobulin knockout (beta2M-/-) mice with irradiated

231 beta(2)-Microglobulin knockout animals controlled infections sim

232 Beta(2)-microglobulin knockout mice displayed significantly incr

233 As beta(2)-microglobulin knockout mice lack both CD8(+) T cells and

234 for the increased mortality noted in beta(2)-microglobulin knockout mice.

235 mers containing either human or murine beta2-microglobulin L chains was tested for all five Ly49 rece

236 vity and specificity was achieved with beta2-microglobulin labeled with (131)I or (111)In.

237 D76N or the natural truncated form of beta2-microglobulin lacking the first six N-terminal residues.

238 age, male sex, and elevated levels of beta2-microglobulin, lactate dehydrogenase, and creatinine.

239 f t(4;14), del(17p), and 1q gain and beta(2)-microglobulin less than 5.5 mg/L.

240 = 295), including ISS stage III (serum beta2-microglobulin level > 5.5 mg/L) and high-risk CA or high

241 n = 871), including ISS stage I (serum beta2-microglobulin level < 3.5 mg/L and serum albumin level >

242 High serum beta(2)-microglobulin level and International Staging System sta

243 unt of 35.9 x 10(9)/L and median serum beta2 microglobulin level of 6.45 mg/L were treated.

244 groups, including those based on the beta(2)-microglobulin level, cytogenetic profile, and response a

245 survival include the patient's age, beta(2)-microglobulin level, monoclonal protein level, hemoglobi

246 Low beta-2-microglobulin levels less than 2 mg/L were independently

247 um more frequently had elevated serum beta-2 microglobulin levels, high-risk Rai stage, and were less

248 T cells was measured, as were plasma beta(2)-microglobulin levels.

249 idering how the amyloidogenesis of the beta2-microglobulin mechanism has been scrutinized in depth fo

250 ion and T cell costimulation, that is, beta2-microglobulin, MHC II, CD40, and ICOSL.

251 ction as compared with K(b-/-)D(b-/-)beta(2)-microglobulin(-/-) mice that lack expression of both MHC

252 combined immunodeficiency (NOD/SCID) beta(2) microglobulin(-/-) mice, engrafted with human CD34+ hema

253 main and the non-covalently associated beta2-microglobulin molecule, demonstrating long-range dynamic

254 ecular mechanism by which a novel anti-beta2-microglobulin monoclonal antibody (beta2M mAb), shown to

255 In the absence of beta2 microglobulin, naive CD8 T cells scarcely proliferated i

256 firmed that conformational dynamics of beta2-microglobulin native state in the crystal lattice is in

257 microglobulin knock out mice, the D76N beta2-microglobulin/ Nb24 pre-formed complex, is cleared from

258 In multivariate analysis, beta-2-microglobulin of more than 3.5 microg/mL at diagnosis an

259 The HDF cohort had lower beta2-microglobulin, parathyroid hormone, and high-sensitivity

260 stocompatibility complex (MHC) class I:beta2-microglobulin:peptide complexes, generating an assembly

261 cell infiltration, M protein, albumin, beta2-microglobulin, performance status, International Staging

262 However, the species of beta2-microglobulin populated in the presence of haptoglobin i

263 racts with the prefibrillar species of beta2-microglobulin, preventing its fibril formation and the a

264 The HLA-B *1502/peptide/beta(2)-microglobulin protein complex showed binding affinity to

265 The mouse and human beta2-microglobulin protein orthologs are 70% identical in seq

266 A recombinant form of alpha(1)-microglobulin (rA1M) was recently shown to preserve kidn

267 icroalbumin levels, and the detectable beta2-microglobulin rate increased in the manufacturers group.

268 Small interfering RNA knockdown of beta2-microglobulin reduced the expression of class I H chain

269 Urea and beta2-microglobulin reduction rates were 64.5% +/- 0.4% and 48

270 ultivariate analysis showed that serum beta2-microglobulin (sbeta2M) levels > 2.5 ug/mL (hazard ratio

271 crease in the levels of lactoferrin, beta(2)-microglobulin, sodium, lysozyme C, and cystatin C, and a

272 ell death ligand 1 (PD-L1)(2) and the beta-2 microglobulin subunit of the major histocompatibility cl

273 ha3 domains, as well as the associated beta2-microglobulin subunit.

274 zyme, myoglobin, alpha-synuclein and beta(2)-microglobulin, suggesting that common structural feature

275 HC class I and related genes such as beta(2)-microglobulin, Tap1, or Lmp2, but did not affect MHC cla

276 ass I antigen presentation, including beta-2 microglobulin, (TAP1), and TAP2.

277 approach for the amyloidogenic protein beta2-microglobulin that folds via an intermediate state which

278 ermediate of the amyloidogenic protein beta2-microglobulin that has a half-lifetime of only 20 min.

279 in but not with monomeric or fibrillar beta2-microglobulin that may underlie the molecular mechanism.

280 h plasma concentrations of wild-type beta(2)-microglobulin, the affected members of this kindred had

281 , NLRC5 also induced the expression of beta2-microglobulin, transporter associated with antigen proce

282 r response were age 70 years or older, beta2-microglobulin twice the upper limit of normal (2N) or mo

283 Patients with elevated urine beta-2 microglobulin (Ubeta2M) and a diagnosis of TINU were inc

284 ptoglobin prevents fibril formation of beta2-microglobulin under conditions of physiological acidosis

285 ation, immunoglobulin M, albumin, and beta-2 microglobulin values as continuous measures.

286 enal function and normal circulating beta(2)-microglobulin values.

287 The Asp76Asn beta(2)-microglobulin variant was thermodynamically unstable and

288 biophysical characterization of the beta(2)-microglobulin variant, including its 1.40-A, three-dimen

289 bitor of Metalloproteinases-1 (TIMP1), beta2-Microglobulin, Vascular Endothelial Growth Factor A (VEG

290 ALK-positive and ALK-negative ALCL, beta(2)-microglobulin was >/= 3 mg/L in 12% and 33% (P = .017);

291 genic and nonamyloidogenic variants of beta2-microglobulin, we identify the interactions that inhibit

292 ate analysis, stage C disease and high beta2 microglobulin were independent predictors of a positive

293 rration, advanced Rai stage, and high beta-2 microglobulin were independently associated with inferio

294 s for fully deuterated ubiquitin and beta(2)-microglobulin were observed after 10 min of back-exchang

295 or of metalloproteinase [TIMP]-1, and beta-2-microglobulin) were higher in rAKI versus nAKI (P < 0.05

296 resentation, including MHC class I and beta2 microglobulin, were highly susceptible to mycolactone tr

297 s had lower baseline plasma levels of beta-2-microglobulin, were more likely to have trisomy 12, and

298 hanced by the introduction of human beta(2) -microglobulin, which increases surface expression of MHC

299 Amyloid deposition of WT human beta(2)-microglobulin (WT-hbeta(2)m) in the joints of long-term

300 proteins: Orosomucoid, transferrin, alpha-1 microglobulin, zinc alpha-2 glycoprotein, alpha-1 antitr